Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 1;33(5):486-493.
doi: 10.1097/MNH.0000000000001000. Epub 2024 May 3.

Women's health and kidney protective medications

Mythri Shankar  1 , Sehrish Ali  2 , Silvi Shah  3
Affiliations
Review

Women's health and kidney protective medications

Mythri Shankar et al. Curr Opin Nephrol Hypertens. .

Abstract

Purpose of review: We discuss the sex-based differences in the pharmacokinetics and pharmacodynamics of kidney protective medications and their implications on women's health.

Recent findings: A critical examination of adverse drug reactions highlights the underrepresentation of women in clinical trials for kidney and cardiovascular protective drugs, such as SGLT2 inhibitors, ACE inhibitors, and endothelin receptor antagonists. This underscores the need for sex-specific analyses in clinical studies to accurately assess medication efficacy and safety.

Summary: The research demonstrates that women are more likely to experience adverse events and less likely to benefit from certain treatments, emphasizing the urgent need for healthcare providers to adopt a sex-informed approach in prescribing practices. Future research should prioritize sex differences from the outset to enhance understanding and improve clinical outcomes for women with chronic kidney disease and cardiovascular conditions.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The remaining authors have no conflict of interest.

Figures

Figure 1.
Figure 1.
Sex differences in adverse drug reporting [2].
Figure 2.
Figure 2.
Medications and their effects on women.
Figure 3.
Figure 3.
Target of future research on kidney and cardioprotective medications
See this image and copyright information in PMC

References

    1. Momper JD, Misel ML, McKay DB. Sex differences in transplantation. Transplant Rev (Orlando) 2017; 31:145–150. - PMC - PubMed
    1. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48:143–157. - PMC - PubMed
    1. Sarafidis PA, Memmos E, Alexandrou ME, Papagianni A. Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives. Curr Pharm Des 2018; 24:5528–5536. - PubMed
    1. Bakris GL, Agarwal R, Anker SD et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383:2219–2229. - PubMed
    1. Ruilope LM, Agarwal R, Anker SD et al. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol 2019; 50:345–356. - PMC - PubMed